This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intercept (ICPT) Gains 26.2% YTD: What's in Store?
by Zacks Equity Research
Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 28.57% and 3.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona
by Zacks Equity Research
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View
by Zacks Equity Research
Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
by Zacks Equity Research
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses
by Zacks Equity Research
FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of -50% and 7.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.